Peak Pharmaceuticals Inc. (OTC: CTCO), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, all-natural, hemp-based, medicinal therapies and supplements (Nutraceuticals) for both humans and animals, recently announced the completion of an in-depth analysis of the human and veterinarian supplement markets and the development of a 3-year operations strategy.

The detailed analysis was carried out by two teams of Executive MBA students of the Stephen M. Ross School of Business, at the University of Michigan, over the course of three months. The project scope included assessment and situational analysis of the target market domains including customer segments and channels, an in depth study of the competitive landscape, and a strategy for commercial entry into these markets.

“We were thrilled and gratified by the opportunity to work with the very enthusiastic and professional executives that comprised our two teams,” said Peak Pharmaceuticals Inc. President and CEO Dr. Soren Mogelsvang. “Through this relationship with the Stephen M. Ross School of Business at the University of Michigan, we gained access to invaluable resources, typically beyond the reach of smaller companies such as ours.”

Both EMBA teams delivered their final reports in December, including executive summaries, as well as base case product launch strategies along with a detailed analysis of the company, competitors, customers, collaborators and context (5C’s) across the U.S. nutraceutical/medical hemp market. Additional details included an analysis of segmentation, targeting and positioning, pricing policies, route to market and gaps within current strategies.

“We are really pleased to have such well-researched and detailed ‘roadmaps’ for our ongoing business development activities, aiding both our Canna-Pet™ sales and, perhaps more importantly, with our future aims for human CBD products,” added Dr. Mogelsvang. “This will undoubtedly save tens of thousands of dollars down the road and accelerate our market entry. The information at hand is far more in-depth than pretty much any business plan I’ve ever seen before, and it will serve us very well as we continue to build Peak Pharma into a profitable and sustainable nutraceutical company.”

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: